Abstract: Disclosed herein are methods of disrupting cell-to-cell communication. An exemplary method comprises transmitting one or more microwave signals to a communication molecule located in an environment having a plurality of cells. The one or more microwave signals can comprise a first microwave signal and a second microwave signal. The first microwave signal can have a first frequency corresponding to frequency of a first peak in a microwave spectrum associated with rotational modes of the communication molecule. The second microwave signal can have a second frequency corresponding to a frequency of a second peak in the microwave spectrum associated with the rotational modes of the communication molecule.

Abstract: Provided herein are methods of generating a homologous recombination repair deficiency (HRD) score, determining a reference HRD score, determining a HRD status of a test subject having one or more cancer types, and/or treating a disease based on HRD status. Additional methods as well as related systems, apparatuses, and computer readable media are also provided.

Abstract: A device includes arrays of Non-Volatile Memory (NVM) cells. Reference sequences representing portions of a genome are stored in respective groups of NVM cells. Exact matching phase substring sequences representing portions of at least one sample read are loaded into groups of NVM cells. One or more groups of NVM cells are identified where the stored reference sequence matches the loaded exact matching phase substring sequence using the arrays at Content Addressable Memories (CAMs). Approximate matching phase substring sequences are loaded into groups of NVM cells. One or more groups of NVM cells are identified where the stored reference sequence approximately matches the loaded approximate matching phase substring sequence using the arrays as Ternary CAMs (TCAMs). At least one of the reference sequence and the approximate matching phase substring sequence for each group of NVM cells includes at least one wildcard value when the arrays are used as TCAMs.

Abstract: Methods and devices involving using a bolus calculator to account for an uncertainty of a carbohydrate estimate to reduce a risk of hypoglycemia and/or a risk of hyperglycemia. More specifically, methods and devices using an algorithm executed by a processor of the bolus calculator and using a carbohydrate estimate and a measure defining the uncertainty of the carbohydrate estimate to determine the probability of hypoglycemia and/or hyperglycemia if the carbohydrate estimate is an overestimate or an underestimate, and subsequently providing recommendations and alerts to a user.

Abstract: A closed-loop artificial pancreas system based on a wearable monitoring method is provided.

Abstract: Methods for identifying patients diagnosed with treatment resistant or refractory depression, pain or other clinical indications who are eligible to receive N-methyl-D-aspartate receptor antagonist, glycine receptor beta (GLRB) modulator, or ?-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR)-based therapies to include determining the appropriate medication, an optimal dose for each patient, and determining which patients are not eligible to receive the therapy. The pharmacogenomic clinical decision support assays include targeted single nucleotide polymorphisms and clinical values or a combination of targeted single nucleotide polymorphisms, targeted ketamine-specific expansion and contraction of topologically associated domains, and clinical values. The methods described herein allow for a more effective determination of which patients will experience drug efficacy and which patients will experience adverse drug events.

Abstract: The present invention provides methods of determining a survival predictor score of a subject having mantle cell lymphoma (MCL). The present invention also provides methods of predicting the survival outcome of a subject having MCL and provides methods of selecting a treatment for a subject having MCL.

Abstract: First sensor data may be acquired from a first galvanic skin response sensor monitoring a first user. Second sensor data may be acquired from a second galvanic skin response sensor monitoring a second user. At least one programmable processor may generate a compatibility score between the first user and the second user. The generating may include executing a compatibility algorithm to generate the compatibility score based at least on a comparison of at least one type of response contained in the first sensor data and the second sensor data. A client device may generate an electronic indication of the compatibility score.

Abstract: The use of dianhydrogalactitol provides a novel therapeutic modality for the treatment of glioblastoma multiforme and medulloblastoma. Dianhydrogalactitol acts as an alkylating agent on DNA that creates N7 methylation. Dianhydrogalactitol is effective in suppressing the growth of cancer stem cells and is active against tumors that are refractory to temozolomide; the drug acts independently of the MGMT repair mechanism.

Abstract: Embodiments of techniques for analyzing one or more genomic regions of a genome of an organism. Data about a genomic region may be analyzed to determine an information content of the genomic region, which may indicate an amount of information provided by the genomic region. The data about the genomic region may be or include data identifying a chromatin state for the genomic region. A chromatin state may be one of a set of chromatin states that each define a different set of one or more chromatin characteristics. Chromatin characteristics may be structural and/or functional features of genomic regions. A chromatin state of a genomic region may be determined from, and describe, the genomic region such that when a genomic region has a set of one or more chromatin characteristics, a chromatin state associated with that combination of one or more chromatin characteristics is identified for the genomic region.

Abstract: A biometric device, comprising a solid support suitable for receiving biological material and for dry storing that material at room temperature the device further comprising a circuit including means for two way radio frequency communication and including writable data storage. A processing method for such biometric devices, the method including the steps of: a) identifying said device by means of RF communication; b) extracting at least a portion of the biological material from the solid support of the identified device; c) analysing the extracted biological material to obtain biometric data indicative of the biological material; and d) writing said biometric data to the data storage of the biometric device.

Abstract: A conformation analysis device and analysis method with which discrimination can be achieved even if there is a subtle difference in a conformational structure, a given molecule can be processed in a unified manner, and large-scale computer processing can be performed, and a conformational notation device and notation method with which even in the case where a conformation cannot be uniquely determined if a rule in accordance with the IUPAC Nomenclature is followed, the conformation can be uniquely notated, a given molecule can be processed in a unified manner, and large-scale computer processing can be performed, are provided.

Abstract: Methods and compositions are provided for the identification of a molecular diagnostic test for cancer. The test identifies cancer subtypes that have an up-regulation or a down-regulation in biomarker expression related to angiogenesis and vascular development. The present invention can be used to determine whether patients with cancer are clinically responsive or non-responsive to a therapeutic regimen prior to administration of any anti-angiogenic agent. This test may be used in different cancer types and with different drugs that directly or indirectly affect angiogenesis or angiogenesis signalling. In addition, the present invention may be used as a prognostic indicator for certain cancer types. In particular, the present invention is directed to the use of certain combinations of predictive markers, wherein the expression of the predictive markers correlates with responsiveness or non-responsiveness to a therapeutic regimen.

Abstract: A method for predicting drug concentration levels includes receiving at least one subject characteristic of the subject, and executing a full body circulation model by: determining a first concentration of the drug in a first blood flow entering a first organ determining a second concentration of the drug in the first organ, determining a third concentration of a drug in a third blood flow entering a second organ, the third blood flow downstream of the first organ, and determining, using the second organ model a fourth concentration of the drug in the second organ.

Abstract: The present invention relates to amylin analogs and to their use in the treatment or prevention of a variety of diseases, conditions or disorders, including obesity, excess food intake and associated metabolic diseases such as diabetes. The analogs have good physical and chemical stability, good solubility, and a long duration of action, and are well suited for use in the form of a liquid formulation.

Abstract: The invention relates to isolated peptides and chimeric polypeptides derived from Saposin A that have anti-angiogenic activity. These peptides are small, consisting essentially of at least 10 consecutive amino acid residues from the 31st-50th amino acid residue of Saposin A. The invention also relates to the use of these isolated peptides and chimeric polypeptides in compositions for the treatment, prevention, and inhibition of angiogenesis-related diseases and disorders such as cancer and cancer metastasis.

Abstract: The present invention relates to a compound of the Formula (I)): or pharmaceutically acceptable salt thereof, wherein the symbols are as defined in the specification; a pharmaceutical composition comprising the same, a method for treating or preventing viral infections, inflammation, dry eye, central nervous disorders, cardiovascular diseases, cancer, obesity, diabetes, muscular dystrophy, and hair loss.

Abstract: Disclosed is a highly efficient method for production of highly pure mutant-type human erythropoietin. The method is for production of mutant-type human erythropoietin, in which a transformed mammalian cell is allowed to produce the mutant-type human erythropoietin, and the supernatant of the culture is subjected to hydrophobic column chromatography, multimodal anion exchange column chromatography, anion exchange column chromatography, phosphate group affinity column chromatography, and gel filtration column chromatography, in this order.

Abstract: The present invention provides kits and methods for detecting peptides that change of the fluorescence of dyes upon binding to the dye. In addition, the invention provides methods for identifying said peptides.

Abstract: Described herein are methods of syntheses and therapeutic uses of covalently modified peptides and/or proteins. The covalently modified peptides and/or proteins allow for improved pharmaceutical properties of peptide and protein-based therapeutics.